Windtree Therapeutics (WINT) Emerging Growth Conference77 summary

Strategic focus and drug profile

• Lead candidate Istaroxime targets cardiogenic shock, a severe form of heart failure with high mortality and limited treatment options.

• Istaroxime is a first-in-class dual mechanism agent, activating SERCA2a and strengthening heart contractions while improving relaxation between beats.

• Four positive phase II studies have shown consistent efficacy across diverse patient populations, with over 300 patients treated.

• Fast Track designation was granted by the FDA, and regulatory discussions highlighted a straightforward approval pathway based on blood pressure improvement.

• Scientific advisors and market research confirm strong clinical need and high physician interest in innovative therapies for cardiogenic shock.

Clinical results and safety

• Istaroxime increases systolic blood pressure and cardiac output without raising heart rate, often lowering it, which reduces myocardial oxygen demand.

• The drug improves renal function and reduces pulmonary congestion, with no significant increase in arrhythmias observed in studies.

• SEISMIC studies demonstrated rapid, significant, and sustained improvements in blood pressure, cardiac output, and organ perfusion.

• Serious adverse events were fewer in the Istaroxime group compared to placebo, with notable reductions in worsening heart failure.

• Composite endpoints suggest reduced risk of heart failure events, readmissions, and death, though statistical significance awaits larger studies.

Development strategy and market opportunity

• Cardiogenic shock market was valued at $1.25 billion in 2020, projected to reach $3 billion by 2039.

• Next-generation SERCA2a activators are in preclinical development for chronic heart failure and outpatient use.

• A licensing partner in Greater China will conduct a phase III acute heart failure study, and additional licensing opportunities are being pursued.

• SEISMIC Extension and SEISMIC C studies are ongoing, with preliminary readouts expected in the first half of next year, supporting phase III readiness.

• Phase III program is expected to enroll 300–400 patients, focusing on blood pressure as the primary endpoint and health economic outcomes.